# SLFN11

Source: https://onco.cc/targets/slfn11/  
OnCo record `slfn11` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SLFN11 (Schlafen family member 11) is an enzyme. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Ewing sarcoma and Small-cell lung cancer.

## Summary

Inhibitor of DNA replication that promotes cell death in response to DNA damage. Acts as a guardian of the genome by killing cells with defective replication. Persistently blocks stressed replication forks by opening chromatin across replication initiation sites at stressed replication forks, possibly leading to unwind DNA ahead of the MCM helicase and block fork progression, ultimately leading to cell death.

CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Temozolomide, 7-Ethyl-10-Hydroxycamptothecin, Talazoparib and Niraparib.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: schlafen family member 11; Schlafen family member 11; FLJ34922
- Tags: cancer-genes-wave
- Symbol: SLFN11
- Class: enzyme
- Biology: Inhibitor of DNA replication that promotes cell death in response to DNA damage. Acts as a guardian of the genome by killing cells with defective replication. Persistently blocks stressed replication forks by opening chromatin across replication initiation sites at stressed replication forks, possibly leading to unwind DNA ahead of the MCM helicase and block fork progression, ultimately leading to cell death. Upon DNA damage, inhibits translation of ATR or ATM based on distinct codon usage without disrupting early DNA damage response signalling. Antiviral restriction factor with manganese-dependent type II tRNA endoribonuclease. A single tRNA molecule is bound and cleaved by the SLFN11 dimer. Location: Nucleus; Chromosome (UniProt). Locus 17q12 (HGNC).
- Where found: Colorectal cancer: CIViC evidence names this disease; Ewing sarcoma: CIViC evidence names this disease; Small-cell lung cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 4 therapies; CIViC holds 3 clinical evidence items on its variants; UniProt keyword "DNA damage". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:26633: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26633
- UniProt Q7Z7L1: https://www.uniprot.org/uniprotkb/Q7Z7L1/entry
- NCBI Gene 91607: https://www.ncbi.nlm.nih.gov/gene/91607
- Ensembl ENSG00000172716: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172716

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)

---
JSON: https://onco.cc/api/v1/entities/slfn11.json